Everolimus and lenvatinib for bone sarcoma
Treatments studied
Part of Bones, joints & muscles, Cancer clinical trials.
This study tests whether combining two targeted drugs, everolimus and lenvatinib, is better than everolimus alone for people with advanced bone sarcoma. These drugs work by blocking signals that help cancer cells grow and by cutting off the blood supply to tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced osteosarcoma, Ewing sarcoma, or chondrosarcoma that has spread or cannot be removed with surgery.
- You have had 1 or 2 prior chemotherapy treatments (including neoadjuvant or adjuvant therapy).
- You are 19 to under 80 years old.
- You are physically active and able to care for yourself (ECOG performance status 0-1).
- You have at least one tumor that can be measured on imaging scans.
- You have adequate organ function, as determined by blood tests for hemoglobin, white blood cells, platelets, kidneys, and liver.
- You have not previously been treated with everolimus, lenvatinib, or any other mTOR inhibitor.
- You have no active infections, serious heart problems within the past 6 months, or other cancers (except for certain early-stage skin cancer or cervical cancer).
- You have no untreated or growing brain metastases.
- You are willing to use effective birth control during the study and for 90 days after the last dose.
- You can provide written informed consent and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
This trial tests a combination of three drugs (dinutuximab beta, irinotecan, and rapamycin) for people with bone cancers like osteosarcoma or Ewing sarcoma that have come back or not responded to treatment. The goal is to see if this combination can shrink or slow the tumors.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
Hear when a new Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical Site trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.